Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

159.00 +1.10 (+0.70%)
Streaming Delayed Price Updated: 1:23 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
48 49 Next >
US Senate Narrowly Votes In Favor Of Biden's Nominee Robert Califf To Lead FDA For Second Time
By a narrow vote of 50-46, the Senate has confirmed Robert Califf to run the FDA. Califf, who previously served as the FDA commissioner from February 2016 to January... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector. 
Via Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
What 24 Analyst Ratings Have To Say About Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings For Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter: 
Via Benzinga
BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Biogen Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Biogen Class Action Reminder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Biogen: Q4 Earnings Insights
  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Biogen Shareholder Notice
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Biogen Shareholder Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Biogen Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have  
Via Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Monday
BMO Capital cut the price target for Match Group, Inc. (NASDAQ: MTCH) from $150 to $130. Match Group shares fell 1.4% to trade at $114.33 on Monday. 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came... 
Via Talk Markets
Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes
The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm... 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
The major indexes slashed weekly gains after Monday's follow-through day. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2022
Upgrades CBRE upgraded the previous rating for Penn National Gaming Inc (NASDAQ:PENN) from Hold to Buy. For the fourth quarter, Penn National Gaming had an EPS of $0.26,... 
Via Benzinga
10 Biggest Price Target Changes For Friday
JP Morgan boosted the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $4,350 to $4,500. Amazon shares jumped 11% to $3,081.07 in pre-market trading. 
Via Benzinga
Facebook FB plunges but Amazon AMZN surges: Earnings and Your Updated Price Levels
It seems like yesterday we were discussing the surge in Alphabet shares, and today we're focusing on big moves - currently in opposite directions - of Facebook and Amazon, all major market cap... 
Via Talk Markets
Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus
Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $ 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.